Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ELI LILLY AND COMPANY

(LLY)
  Report
Delayed Nyse  -  04:03 2022-12-06 pm EST
368.54 USD   -0.20%
08:01aPhase III trial demonstrated Jardiance« is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes
PR
12/06Eli Lilly Says Follow-up Data from Phase 3 Verzenio Trial Show Continued Increase in Survival in Breast Cancer Patients
MT
12/06Major Pharma Companies to Remain Defensive Through at least H1 2023 Amid M&As, New Products Focus, Morgan Stanley Says
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Eli Lilly Faces US Lawsuit Over Age Discrimination In Sales Jobs

09/27/2022 | 12:04am EST


ę MT Newswires 2022
All news about ELI LILLY AND COMPANY
08:01aPhase III trial demonstrated Jardiance« is the first SGLT2 inhibitor to show statistica..
PR
12/06Eli Lilly Says Follow-up Data from Phase 3 Verzenio Trial Show Continued Increase in Su..
MT
12/06Major Pharma Companies to Remain Defensive Through at least H1 2023 Amid M&As, New Prod..
MT
12/06Credit Suisse Raises Eli Lilly's Price Target to $400 From $395, Keeps Outperform Ratin..
MT
12/06Morgan Stanley Boosts Price Target on Eli Lilly to $446 From $436, Maintains Overweight..
MT
12/06Chronic Lower Back Pain Pipeline Offers Novel Treatment Options | 10+ Companies & 10+ D..
AQ
12/05Cowen Boosts Price Target on Eli Lilly to $430 From $390, Maintains Outperform Rating
MT
12/05SonoThera announced that it has received $60.75 million in funding from a group of inve..
CI
12/03Amgen says experimental obesity drug has promising durability
RE
12/01Eli Lilly and Co.'s Unit Completes Negotiations With Canadian Drug Accessibility Allian..
MT
More news
Analyst Recommendations on ELI LILLY AND COMPANY
More recommendations
Financials (USD)
Sales 2022 28 688 M - -
Net income 2022 6 187 M - -
Net Debt 2022 10 498 M - -
P/E ratio 2022 55,3x
Yield 2022 1,01%
Capitalization 350 B 350 B -
EV / Sales 2022 12,6x
EV / Sales 2023 11,9x
Nbr of Employees 35 000
Free-Float 99,8%
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 368,54 $
Average target price 373,82 $
Spread / Average Target 1,43%
EPS Revisions
Managers and Directors
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Diogo Rau Senior VP, Chief Information & Digital Officer
Alonzo Weems Senior VP, Chief Ethics & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
ELI LILLY AND COMPANY33.69%350 179
JOHNSON & JOHNSON4.51%460 411
ABBVIE INC.20.92%289 437
NOVO NORDISK A/S21.77%285 921
PFIZER, INC.-14.09%279 038
MERCK & CO., INC.42.13%276 181